Advertisement

Dapsone and Retinoids

  • David Bacman
  • Annegret Kuhn
  • Thomas Ruzicka

Keywords

Bullous Pemphigoid Meibomian Gland Cutaneous Lupus Erythematosus Discoid Lupus Erythematosus Subacute Cutaneous Lupus Erythematosus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allen JG, Bloxham DP (1989) The pharmacology and pharmacokinetics of the retinoids. Pharmacol Ther 40:1–27CrossRefGoogle Scholar
  2. Brecher AR, Orlow SJ (2003) Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol. 49:171–182CrossRefPubMedGoogle Scholar
  3. Callen JP (1990) Treatment of cutaneous lesions in patients with lupus erythematosus. Dermatol Clin 8:355–365PubMedGoogle Scholar
  4. Coburn PR, Shuster S (1982) Dapsone and discoid lupus erythematosus. Br J Dermatol 106:105–106PubMedGoogle Scholar
  5. Coleman MD (1993) Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 129:507–513PubMedGoogle Scholar
  6. Craven NM, Griffiths CE (1996) Topical retinoids and cutaneous biology. Clin Exp Dermatol 21:1–10CrossRefPubMedGoogle Scholar
  7. Duna GF, Cash JM (1995) Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 21:99–115PubMedGoogle Scholar
  8. Duken CM (1984) Retinoids: a review. J Am Acad Dermatol 11:541–552PubMedGoogle Scholar
  9. Ellis CN, Krach KJ (2001) Uses and complications of isotretinoin therapy. J Am Acad Dermatol 45:S150–157CrossRefPubMedGoogle Scholar
  10. Furner BB (1990a) Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 29:542–547PubMedGoogle Scholar
  11. Furner BB (1990b) Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol 29:587–590PubMedGoogle Scholar
  12. Grupper C, Berretti B (1984) Lupus erythematosus and etretinate. In: Cunliffe WJ, Miller AJ (eds) Retinoid therapy. MTP, Lancaster, pp 73–82Google Scholar
  13. Hall RP, Lawley TJ, Smith HR, Katz SI (1982) Bullous eruption of systemic lupus erythematosus. Ann Intern Med 97:165–170PubMedGoogle Scholar
  14. Katz SI (1999) Sulfones. In: Freeberg MI, Eisen ZA, Wolff K, Austen FK, Goldsmith AL, Katz IS, Fitzpatrick BT (eds) Dermatology in general medicine, 5th ed. McGraw-Hill, New York, pp 2790–2794Google Scholar
  15. Katz HI, Waalen J, Leach EE (1999) Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol 41:S7–S12PubMedGoogle Scholar
  16. Kuhn A, Richter-Hintz D, Oslislo C, Ruzicka T, Megahed M, Lehmann P (2000) Lupus erythematosus tumidus — a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 136:1033–1041PubMedGoogle Scholar
  17. Lang PG Jr (1979) Sulfones and sulfonamides in dermatology today. J Am Acad Dermatol 1:479–492PubMedGoogle Scholar
  18. Lindskov R, Reymann F (1986) Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 172:214–217PubMedGoogle Scholar
  19. Lo JS, Berg RE, Tomecki KJ (1989) Treatment of discoid lupus erythematosus. Int J Dermatol 28:497–507PubMedGoogle Scholar
  20. Lubach D, Wagner G (1984) Erfolgreiche Behandlung eines subakut kutanen Lupus erythematodes mit Etretinat. Aktuel Dermatol 10:142–144Google Scholar
  21. Lucek RW, Colburn WA (1989) Clinical pharmacokinetics of the retinoids. Clin Pharmacokinet 10:38–62Google Scholar
  22. McCormack LS, Elgart ML, Turner ML (1984) Annular subacute cutaneous lupus erythematosus responsive to dapsone. J Am Acad Dermatol 11:397–401PubMedGoogle Scholar
  23. Miyachi Y, Niwa Y (1982) Effects of KI, colchicine and dapsone on the generation of PMNL-derived oxygen intermediates. Br J Dermatol 107:209–214PubMedGoogle Scholar
  24. Mok CC, Lau CS (1996) Dapsone syndrome in cutaneous lupus erythematosus. J Rheumatol 23:766–768PubMedGoogle Scholar
  25. Mok CC, Lau CS, Wong RW (1998) Toxicities of dapsone in the treatment of cutaneous manifestations of rheumatic diseases. J Rheumatol 25:1246–1247PubMedGoogle Scholar
  26. Newton RC, Jorizzo JL, Solomon AR Jr, Sanchez RL, Daniels JC, Bell JD, Cavallo T (1986) Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol 122:170–176CrossRefPubMedGoogle Scholar
  27. Orfanos CE, Ehlert R, Gollnick H (1987) The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 34:459–503PubMedGoogle Scholar
  28. Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC (1997) Current use and future potential role of retinoids in dermatology. Drugs 53:358–388PubMedGoogle Scholar
  29. Peck GL, DiGiovanna JJ (1999) Retinoids. In: Freeberg MI, Eisen ZA, Wolff K, Austen FK, Goldsmith AL, Katz IS, Fitzpatrick BT (eds) Dermatology in general medicine. 5th ed. McGraw-Hill, New York, pp 2810–2821Google Scholar
  30. Pfeiffer C, Wozel G (2003) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 48:308–309CrossRefPubMedGoogle Scholar
  31. Ruzicka T, Goerz G (1981) Dapsone in the treatment of lupus erythematosus. Br J Dermatol 104:53–56PubMedGoogle Scholar
  32. Ruzicka T, Wasserman SI, Soter NA, Printz MP (1983) Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapsone. J Allergy Clin Immunol 72:365–370CrossRefPubMedGoogle Scholar
  33. Ruzicka T, Meurer M, Braun-Falco O (1985) Treatment of cutaneous lupus erythematosus with etretinate. Acta Derm Venereol 65:324–329PubMedGoogle Scholar
  34. Ruzicka T, Meurer M, Bieber T (1988) Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol 124:897–902CrossRefPubMedGoogle Scholar
  35. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H (1992) Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 127:513–518PubMedGoogle Scholar
  36. Shornick JK, Formica N, Parke AL (1991) Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 24:49–52PubMedGoogle Scholar
  37. Wiegand UW, Chou RC (1998) Pharmacokinetics of oral isotretinoin. J Am Acad Dermatol 39:S8–12PubMedGoogle Scholar
  38. Wiegand UW, Chou RC (1998) Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol 39:S25–33PubMedGoogle Scholar
  39. Windhorst DB (1982) The use of isotretinoin in disorders of keratinisation. J Am Acad Dermatol 6:708–709PubMedGoogle Scholar
  40. Wozel G, Barth J (1988) Current aspects of modes of action of dapsone. Int J Dermatol 27:547–552PubMedGoogle Scholar
  41. Zhu YI, Stiller MJ (2001) Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 45:420–434CrossRefPubMedGoogle Scholar
  42. Zuidema J, Hilbers-Modderman ES, Merkus FW (1986) Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 11:299–315PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 2005

Authors and Affiliations

  • David Bacman
  • Annegret Kuhn
  • Thomas Ruzicka

There are no affiliations available

Personalised recommendations